<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03645499</url>
  </required_header>
  <id_info>
    <org_study_id>DSTO 1723</org_study_id>
    <nct_id>NCT03645499</nct_id>
  </id_info>
  <brief_title>An Open-Label Study to Assess Safety</brief_title>
  <official_title>An Open-Label Study to Assess the Efficacy and Potential for Adrenal Suppression Following Maximal Use Treatment With TA-102 Topical Formulations in Subjects With Plaque Psoriasis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label study to assess safety
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An Open-Label study to assess the efficacy and potential for adrenal suppression following
      maximal use treatment with TA-102 topical formulations in subjects with Plaque Psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 4, 2018</start_date>
  <completion_date type="Anticipated">December 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of participants with adrenal suppression</measure>
    <time_frame>84 Days</time_frame>
    <description>number of participants with adrenal suppression developed during the treatment with the study drug</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Topical TA-102 A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TA-102 B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TA-102 C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TA-102 D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical TA-102 E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A thin layer of the study medication will be applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA-102 A</intervention_name>
    <description>applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks</description>
    <arm_group_label>Topical TA-102 A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA-102 B</intervention_name>
    <description>applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks</description>
    <arm_group_label>Topical TA-102 B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA-102 C</intervention_name>
    <description>applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks</description>
    <arm_group_label>Topical TA-102 C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA-102 D</intervention_name>
    <description>applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks</description>
    <arm_group_label>Topical TA-102 D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical TA-102 E</intervention_name>
    <description>applied smoothly and evenly to affected areas (excluding face, axilla and groin areas) once daily for 12 weeks</description>
    <arm_group_label>Topical TA-102 E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or non-pregnant female aged â‰¥ 18 years with a clinical diagnosis of
             plaque psoriasis.

          2. Definite clinical diagnosis of stable plaque psoriasis for at least 6 months.

          3. Subjects must be in good health and free from any clinically significant disease,
             including but not limited to, conditions that may interfere with the evaluation of
             plaque psoriasis.

        Exclusion Criteria:

          1. Female Subjects who are pregnant, nursing or planning to become pregnant during study
             participation.

          2. History of allergy or sensitivity to retinoid, corticosteroids and/or history of any
             drug hypersensitivity or intolerance which, in the opinion of the Investigator, would
             compromise the safety of the Subject or the results of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catawba Research, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

